Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.

摘要: Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for selection cancer patients trastuzumab therapy. Amplification gene analysed by fluorescence situ hybridisation (FISH) or overexpression protein determined immunohistochemistry (IHC) are two major methods to establish this status. A strong correlation been previously demonstrated between these methods. However, FISH is not always feasible routine practice and weakly positive IHC tumours (2+) do correspond a amplification. Our study was performed order evaluate contribution chromogenic (CISH), which enables detection copies through an immunoperoxidase reaction. CISH 79 carcinomas HER2 FISH. The results IHC, were compared each tumour. procedures successful 95% our cases. Whatever results, we found very good concordance (96%) confirms that may be alternative determination amplification 2+ tumours. allow us think that, many laboratories, also excellent method calibrate or, as quality control test, check regularly signal agreement with